{"denoms":[{"counts":[{"groupId":"BG000","value":"256"},{"groupId":"BG001","value":"256"},{"groupId":"BG002","value":"512"}],"units":"Participants"}],"groups":[{"description":"Tislelizumab 200 mg intravenously (IV) on Day 1 every 21 days until disease progression, unacceptable toxicity, or other discontinuation criteria were met.","id":"BG000","title":"Tislelizumab"},{"description":"Investigator choice of either paclitaxel 135-175 mg /m² on Day 1 IV every 21 days or 80-100 mg/m\\^2 on a weekly schedule; docetaxel 75 mg/m\\^2 IV on Day 1 every 21 days; or irinotecan 125 mg/m\\^2 IV on Days 1 and 8 every 21 days","id":"BG001","title":"Investigator Chosen Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"8.41","value":"61.8"},{"groupId":"BG001","spread":"8.02","value":"61.8"},{"groupId":"BG002","spread":"8.21","value":"61.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"80"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"217"},{"groupId":"BG001","value":"215"},{"groupId":"BG002","value":"432"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"252"},{"groupId":"BG001","value":"252"},{"groupId":"BG002","value":"504"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"201"},{"groupId":"BG001","value":"207"},{"groupId":"BG002","value":"408"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"97"}],"title":"White or Caucasian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Not Reported"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"title":"Unknown"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Other"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"127"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"190"},{"groupId":"BG001","value":"195"},{"groupId":"BG002","value":"385"}],"title":"1"}]}],"description":"Measure Description: ECOG performance status is used by doctors and researchers to assess how a participant's disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis. 0 = Fully Active (Most Favorable Activity); 1 = Restricted activity but ambulatory; 2 = Ambulatory but unable to carry out work activities; 3 = Limited Self-Care; 4 = Completely Disabled, No self-care (Least Favorable Activity)","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status Score","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"142"}],"title":"vCPS >= 10%"},{"measurements":[{"groupId":"BG000","value":"100"},{"groupId":"BG001","value":"122"},{"groupId":"BG002","value":"222"}],"title":"vCPS < 10%"},{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"148"}],"title":"Missing"}]}],"description":"Measure Description: Programmed death ligand 1 (PD-L1) positive is defined as visually-estimated Combined Positive Score (vCPS) \\>= 10%, PD-L1 negative is defined as vCPS \\< 10%, PD-L1 missing refers to the participants without sample collection, not evaluable at baseline, or scored with unqualified sample.\n\nNote terminology was updated from vCPS to Tumor Area Positivity (TAP) score in manuscripts.","paramType":"COUNT_OF_PARTICIPANTS","title":"PD-L1 Expression Status","unitOfMeasure":"Participants"}]}